FDA Relabels Carbamazepine to Recommend Genetic Test for Risk of Skin Reactions | GenomeWeb
NEW YORK (GenomeWeb News) – Patients of Asian ancestry taking the drug carbamazepine will now be advised to take a genetic test to determine whether they have a heightened risk of developing a rare but serious skin reaction, the US Food and Drug Administration said in a statement today. 
Carbamazepine treats epilepsy, bipolar disorder, and neuropathic pain, and is sold under the brand names Carbatrol, Equetro, and Tegretol by Shire Pharmaceuticals, Validus Pharmaceuticals, and Novartis, respectively.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.